The sepsis diagnostics market heated up during the year, with FDA clearances for a handful of tests, growing investor interest, and R&D advances in the field.
The firm's CEO said that the test must undergo additional clinical studies, but it could be available from a CLIA-certified lab in about a year and a half.
The firm's transplant allograft status test identifies genetic biomarkers that predict the likelihood of a patient's immune system to reject the organ over time.
